​​

Stramsen Biotech recently received constructive written feedback from the U.S. Food and Drug Administration (FDA) following the Pre-Investigational New Drug (Pre-IND) submission for SBX-1977. This feedback serves as a pivotal milestone in the regulatory pathway for the company's lead topical botanical drug candidate. SBX-1977 is a novel, plant-derived pharmaceutical gel engineered specifically to facilitate rapid acute wound healing and primary closure.
 

As the flagship asset in the Stramsen Biotech pharmaceutical pipeline, SBX-1977 leverages a sophisticated phytochemical profile to address unmet needs in wound care. The therapeutic candidate is designed to provide a multi-faceted approach to tissue repair, combining regenerative properties with robust infection control. Key features and clinical attributes of the candidate include:
 

• Standardized Phytochemical Formula: A proprietary, bioactive gel formulation derived from high-purity, plant-based phytochemicals to ensure batch-to-batch consistency and therapeutic efficacy.

 

• Multimodal Active Mechanisms: Comprehensive preclinical data demonstrate that the candidate actively promotes cell proliferation, accelerates tissue remodeling, and stimulates fibroblast migration.

 

• Antimicrobial Efficacy: The formulation exhibits potent antibacterial properties, significantly reducing the risk of localized infection during the healing process.

 

• Target Indication: The primary clinical focus is the acceleration of acute wound closure and the mitigation of complications associated with delayed healing.
   

Beyond the laboratory, SBX-1977 is supported by a foundation of historical human use, demonstrating safety and efficacy in treating a variety of dermatological challenges. This history includes the successful management of both acute injuries and complex chronic conditions, such as diabetic ulcers. By modernizing this botanical approach through stringent pharmaceutical development, Stramsen Biotech aims to provide a superior solution for patients suffering from slow-healing and high-risk wounds.

​

​